This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
10 May 2018 | North America
Global Tissue Diagnostics Market, Forecast to 2022
Liquid Biopsy for Therapy Monitoring and Reimbursement Cuts Impede Long-term Prospects of Tissue Diagnostics Market
Tissue diagnostic techniques are used to recognize specific antigens in preserved tissues. The process includes slicing thin tissue samples that are treated with a hematoxylin and eosin (H&E) stain, and then are formalin-fixed paraffin-embedded (FFPE) to diagnose tumors and other histopathology specimens. This has traditionally required skilled pat...
$4,950.00 -
09 Apr 2018 | North America
Global Life Sciences Industry Outlook, 2018
Global Life Sciences Industry to Reach $1.5 T by 2022, Driven by Innovative Google, Amazon, Facebook, Apple (GAFA) Partnerships and R&D IT Investments
The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...
$4,950.00 -
15 Feb 2018 | Global
Global Laboratory Products Purchasing Trends, 2017–2018
An End User Perspective on Laboratory Spending Reveals Optimism for Growing 2018 Budgets
Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in July 2017 that centered around the state of their laboratories in 2017 and their expectations for 2018. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-over...
$1,500.00 -
06 Feb 2018 | Global
Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020
Digitization Presents Opportunities for Unified Cloud-based Platform Solutions to Optimize Clinical Trial Workflows
The global clinical trial IT market is expected to grow from $2.63 billion in 2016 to $4.29 billion in 2020 at a compound annual growth rate (CAGR) of more than 13.0%. North America will continue to hold the largest market share (by revenue) in 2017, followed by Europe. Increasing clinical trial activities in the emerging Asia-Pacific markets and r...
$4,950.00 -
10 Jan 2018 | Asia Pacific
APAC Biosimilar Market, Forecast 2025
Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Ko...
$4,950.00
